Compliance Radar

Who was sanctioned, and for what?

Fines, court rulings and incidents from Europe and North America: 756 cases from 32 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.

Capital markets and financial supervision Chemicals and pharmaceuticals Caroline J. Campbell (Beschäftigte der ImmunityBio, Inc.) Clear all filters

1case from 1 jurisdiction

€288,298Total of monetary amounts

€288,298Largest single case: Caroline J. Campbell (Beschäftigte der ImmunityBio, Inc.)

€288,298Median per case with an amount

Click a bar to drill down one level.

by amount by number of cases

Where?

by region

All jurisdictions

USA €288,298 100 % · 1 case

What for?

by topic

Market abuse and insider dealing €288,298 100 % · 1 case

Who?

by company

When?

per quarter, by date of decision

Trend
Period	Cases	Total
Q3 2023	0	—
Q4 2023	0	—
Q1 2024	0	—
Q2 2024	0	—
Q3 2024	0	—
Q4 2024	0	—
Q1 2025	0	—
Q2 2025	0	—
Q3 2025	0	—
Q4 2025	0	—
Q1 2026	0	—
Q2 2026	1	€288,298
Q3 2026	0	—

1 case

Newest first Highest amounts

6 Apr 2026 Caroline J. Campbell (Beschäftigte der ImmunityBio, Inc.)ImmunityBio employee sells shares ahead of news of FDA delay USAMarket abuse and insider dealing €288,298

In May 2023, an employee of the biotech company sold 48,495 shares with knowledge of the non-public information that the FDA would delay approval of the medicine Anktiva; after the announcement, the share price fell by around 55 %. Under the settlement, she is paying 157,066.28 USD in disgorgement, 18,130.97 USD in interest and a civil penalty of 157,066.28 USD.

What organisations can take from it

Trading bans and blackout periods must be known to all employees with access to approval or trial data, not just to the management board.

Relevance to training and awareness

Insider trading ban for employees, handling of approval information

Authority / court: U.S. Securities and Exchange Commission (SEC)
Area of law: Capital markets and financial supervision · Market abuse and insider dealing
Legal basis: Section 10(b) Securities Exchange Act 1934, Rule 10b-5
Action: Fine
Status of proceedings: final
Sector: Chemicals and pharmaceuticals

Original amount 332,263.53 USD, converted at the ECB reference rate of 2 Apr 2026.

Sources

SEC Files Settled Insider Trading Charges Against California Biotech Employee Decision of an authority

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

How the radar is compiled

Official sources only

Every case is based on a decision, press release or database of an authority or a court. Press and law-firm reports count at most as additional references.

Four-eyes check

Whoever enters a case may not approve it. A second, independent check compares company, date, amount and area of law with the source. Only then is the case published.

Comparable amounts

Amounts are converted at the ECB reference rate on the day of the decision. Each case also shows the original amount.

Corrections on record

A correction is a new version that is checked again. Every change is logged. You can report errors directly on each case.

Case texts are translated from the German original. Where a translation is not yet available, the German text is shown and marked “(German original)”. Names of authorities, laws and companies are given as in the source.

The radar reports on published decisions and is not legal advice. Decisions that are not yet final are marked as such where the status is known.

Embed the radar on your website

Who was sanctioned, and for what?

Ready for training that sticks?